Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: Results of the prospective, single-centre CESSATION study

Heart

Volumn 97, Issue 20, 2011, Pages 1661-1667

  Sambu, Nalyaka ^a,b   Dent, Hazel ^b   Englyst, Nicola ^b   Warner, Timothy D ^c   Leadbeater, Philip ^d   Roderick, Paul ^b   Gray, Huon ^a   Simpson, Iain ^a   Corbett, Simon ^a   Calver, Alison ^a   Morgan, John ^a,b   Curzen, Nick ^a,b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CD40 LIGAND; CLOPIDOGREL; CYCLO OXYGENASE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; ORAL ANTIDIABETIC AGENT; PACLITAXEL; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; RAPAMYCIN; STATIN; THROMBOXANE B2; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD SAMPLING; CESSATION STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTAGLANDIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TYPES OF STUDY;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOXANE B2; TICLOPIDINE; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 80053185590     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300192     Document Type: Article

References (34)

1. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on perctaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41.
2. Berger PB. Optimal duration of clopidogrel use after implantation of drug-eluting stents-still in doubt. N Engl J Med 2010;362:1441-3.
3. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82.
4. http://www.clinicaltrials.gov/ct2/show/NCT00977938?term=DAPT+and +antiplatelet+therapy&rank=3.
5. Ho PM, Tsai TT, Wang TY, et al. Adverse events after stopping clopidogrel in postacute coronary syndrome patients. Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes 2010;3:303-8.
6. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9. (Pubitemid 351222546)
7. Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a "rebound" phenomenon? Thromb Haemost 2011;105:211-20. [Epub ahead of print].
8. Wykrzykowska JJ, Warnholtz A, De Jaeger P, et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-Selectin and CRP levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis 2009;28:410-17.
9. Sibbing D, Stegherr J, Braun S, et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 2010;55:558-65.
10. Angiolillo DJ, Fernandez-ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55:780-4. (Pubitemid 43343236)
11. Hobson AR, Qureshi Z, Banks P, et al. Effects of clopidogrel on "aspirin-specific" pathways of platelet inhibition. Platelets 2009;20:386-90.
12. Armstrong PC, Dhanji AR, Tucker AT, et al. Reduction of platelet thromboxane A2 production ex-vivo and in-vivo by clopidogrel therapy. J Thromb Haemost 2010;8:613-15.
13. Shankar H, Garcia A, Prabhakar J, et al. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006;4:638-47.
14. Hobson AR, Petley GW, Dawkins KD, et al. A novel 15 minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007;18:497-505. (Pubitemid 350034856)
15. Hobson AR, Petley G, Morton G, et al. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with drug-eluting stent thrombosis whilst on dual antiplatelet therapy. Thromb J 2008;21:1-6.
16. Hobson AR, Dawkins KD, Curzen NP. Antiplatelet effects of licking an aspirin tablet can be detected by thrombelastography. Acute Card Care 2008;10:62-3. (Pubitemid 351878183)
17. Hobson AR, Qureshi Z, Banks P, et al. Gender and responses to aspirin and clopidogrel: Insights using short thrombelastography. Cardiovasc Ther 2009;27:246-52.
18. Cotton JM, Worrall AM, Hobson AR, et al. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? Cardiovasc Ther 2010;28:139-46.
19. Sambu N, Hobson A, Curzen N. "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility. Platelets 2011;22:210-16. [Epub ahead of print].
20. Swallow RA, Agarwala RA, Dawkins KD, et al. Thrombelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 2006;17:385-92. (Pubitemid 44410502)
21. Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic-acid induced platelet activation via an adenosine diphosphate-dependent but a cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700 patient study of aspirin resistance. Circulation 2006;113:2888-96. (Pubitemid 44297229)
22. Warner TD, Armstrong PC, Curzen NP, et al. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical; risk in the presence of potent P2Y12 receptor antagonists? Heart 2010;96:1693-4.
23. Englyst NA, Horsfiled G, Kwan J, et al. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 2008;28:1196-203. (Pubitemid 351733359)
24. Heeschen C, Dimmeler S, Hamm CW, et al; for the CAPTURE Study Investigators. Soluble CD40 Ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11. (Pubitemid 36337321)
25. Dosh K, Berger PB, Marso S, et al. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv 2009;2:503-12.
26. Hojo Y, Ikeda U, Katsuki T, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty is a risk factor for restenosis. Heart 2000;84:83-7. (Pubitemid 30429230)
27. Vivekanathan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel pretretament on periprocedural rise in C reactive protein after percutaneous coronary intervention. Am J Cardiol 2004;94:358-60. (Pubitemid 38962706)
28. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-4. (Pubitemid 32831103)
29. Yip HK, Chang LT, Sun CK, et al. Impact of clopidogrel on suppression of circulating levels of soluble CD40 Ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 2006;97:192-4.
30. Vavuranakis M, Latsios G, Aggelis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C reactive protein and soluble CD40 ligand levels. Clin Ther 2006;28:860-71. (Pubitemid 44081951)
31. Azar RR, Kassab R, Zoghbi A, et al. Effects of clopiodgrel on soluble CD40 ligand and on high sensitivity C reactive protein in patients with stable coronary artery disease. Am Heart J 2006;151:521.e1-521.e4.
32. Saw J, Madsen EH, Chan S, et al. The ELAPSE (evaluation of long-term clopidogrel antiplatelet and systemic anti-inflammatory effects) study. J Am Coll Cardiol 2008;52:1826-33.
33. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-9. (Pubitemid 41531626)
34. Craft RM, Chavez JJ, Bresee SJ, et al. A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004;143:301-9. (Pubitemid 38586495)